Pharmafile Logo

SCM Pharma

SCM Pharma is a contract development & manufacturing organisation (CDMO) that develops and makes novel, difficult and dangerous drugs on behalf of our clients. Our formulation development, cGMP manufacturing and aseptic processing services include the sterile filling of liquids, gels and powders (including flammable products) into a range of final dosage forms including ampoules, vials, cartridges, syringes and bottles. So if you’re a pharmaceutical, biotech, medical device or healthcare institution in need of formulation development, clinical manufacturing or contract filling involving a complex product or process – let’s talk.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

No items found

Company Details

Unit 6 Regents Drive, Low Prudhoe Industrial Estate, Prudhoe, Northumberland, NE42 6PX, United Kingdom
+44(0) 1661 833 693

 Latest Content from PMHub 

Pegasus Moves to Brighton

Press Releases | April 29, 2014 | Inizio

Top UK Healthcare Communications Consultancy Moves to Brighton

UX: Designing Human Experiences

Applying science to the creative process to improve lives

08 UX: Pushing the right buttons

Unlocking better outcomes in healthcare with UX

UX: Pushing the right buttons

Unlocking better outcomes in healthcare with UX

07 Good Pharma

Better for patients, better for business

05 Social Media: A Health Hazard?

The case to embrace going social

Creating a Lifeline to the New Digital User

Today, we’re focussed on getting to know our new target: she’s online, mobile, and connected to a large network of friends, information, and marketers who help her make decisions about...

Warehousing of HCV patients reaches new high

White Papers and Resources | December 19, 2013 | Inizio

A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation...

Brand leaders in RA will lose market share, predict rheumatologists

White Papers and Resources | December 19, 2013 | Inizio

Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.